8-K: Oncotelic Therapeutics Completes Merger, Acquires IP Assets

Oncotelic Therapeutics, Inc. announced the completion of a merger involving its subsidiary Oncotelic Inc. and Lunai Bioworks, Inc., resulting in the acquisition of significant intellectual property assets.

Summary

• Oncotelic Therapeutics, Inc. (the Company) completed a merger on May 1, 2026, where its subsidiary, Oncotelic Inc., merged with Lunai Bioworks, Inc. (Lunai).
• The merger involved the acquisition of a multi-jurisdictional patent portfolio from Holdings, which was owned 62.5% by Oncotelic Inc. and 37.5% by Pelerin Therapeutics Inc.
• In consideration for the merger, Lunai issued 8 shares of Series B Convertible Preferred Stock to the Holders, with an aggregate stated value of $20,000,000. Oncotelic Inc. received 5 shares valued at $12,500,000.
• The Company also entered into an Asset Transfer Agreement with Autotelic Inc. to acquire various peptide and hormone-related assets, including intellectual property, know-how, and delivery platforms.
• In exchange for the assets from Autotelic Inc., the Company will issue 10% of its fully diluted outstanding shares upon an uplisting to NYSE/NASDAQ. No cash was paid for this transfer.
• The Company received a broad, royalty-free license back for the intellectual property transferred to Lunai, excluding specific fields (Biodefense and Alzheimer's Disease).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies strategic asset acquisition and IP consolidation, but the potential for significant dilution and the contingent nature of the Autotelic equity issuance temper the enthusiasm.

Positives

• Acquisition of a significant multi-jurisdictional patent portfolio.
• Secured a broad, perpetual, irrevocable, royalty-free, exclusive license for key intellectual property assets.
• Acquisition of diverse peptide and hormone-related assets, including delivery platforms, without cash payment.
• Potential for future equity issuance upon successful uplisting to NYSE/NASDAQ.

Negatives

• The Series B Preferred Stock is convertible into common stock at a fixed price of $1.50 per share, which could lead to significant dilution if the stock price is below this conversion price.
• The intellectual property license granted back to Oncotelic excludes the Biodefense Field and the Alzheimer's Disease Field, limiting the scope of its use.
• The issuance of 10% of fully diluted shares to Autotelic Inc. is contingent on an uplisting, creating uncertainty.
• Dr. Trieu, CEO of Oncotelic, has a partial ownership and control in Autotelic Inc., raising potential related-party transaction concerns.

Risks

• Potential for significant dilution of common stock upon conversion of Series B Preferred Stock.
• The value and marketability of the acquired patent portfolio and other assets are not detailed.
• The success of the asset acquisition is contingent on a future uplisting to NYSE/NASDAQ.
• The exclusion of Biodefense and Alzheimer's Disease fields from the IP license back limits potential applications.
• The company has no continuity of revenue-producing activity or operating infrastructure related to the acquired IP from Holdings.

Future Outlook

The Company's future outlook is tied to the successful uplisting of its capital stock to NYSE/NASDAQ, which will trigger the issuance of equity to Autotelic Inc. The conversion of Series B Preferred Stock into common stock is also a key future event, subject to stockholder approval and the prevailing stock price.

Management Comments

• Dr. Trieu, Chairman and CEO of Oncotelic Therapeutics, Inc., is a partial owner and control person in Autotelic Inc.

Industry Context

StockSavvy.ai notes that this transaction reflects a common strategy in the biotechnology sector where companies leverage intellectual property acquisitions and strategic licensing to build a robust pipeline, especially when aiming for uplisting to major exchanges.

Comparison to Industry Standards

• The structure of the merger and IP acquisition is typical for early-stage biotech firms seeking to consolidate assets before a significant financing event or exchange listing.
• The valuation of the Series B Preferred Stock at $20 million for a patent portfolio and related assets is within a range seen for early-stage IP deals, though specific comparable companies are not disclosed in the filing.
• The grant-back of IP rights, excluding specific therapeutic fields, is a standard practice to allow the original owner to retain rights for other applications while the acquiring entity focuses on defined areas.

Related Party Transactions

• Dr. Trieu, Chairman and CEO of Oncotelic Therapeutics, Inc., is a partial owner and control person in Autotelic Inc., which is involved in an asset transfer agreement with the Company.

Stakeholder Impact

• Shareholders may experience dilution if the Series B Preferred Stock is converted into common stock at a price below $1.50.
• Potential shareholders and investors will be monitoring the company's progress towards an NYSE/NASDAQ uplisting.
• Suppliers and creditors are unlikely to be immediately impacted as the transaction focuses on IP and asset acquisition rather than immediate operational expansion.

Next Steps

• Oncotelic Therapeutics, Inc. will pursue an uplisting of its capital stock to NYSE/NASDAQ.
• Upon successful uplisting, the Company will issue 10% of its fully diluted outstanding shares to Autotelic, Inc.
• Stockholder approval will be required for the conversion of Series B Preferred Stock into common stock.

Key Dates

Recommendation

The filing details significant strategic moves involving IP acquisition and a merger, which are positive steps. However, the potential for substantial dilution from the Series B Preferred Stock conversion and the contingent nature of the Autotelic equity issuance warrant a cautious 'hold' recommendation until the uplisting is achieved and the impact of conversions is clearer.

Keywords

Oncotelic Therapeutics, Merger Agreement, Lunai Bioworks, Intellectual Property, Patent Portfolio, Asset Transfer, Series B Preferred Stock, Uplisting